Boule Diagnostics do not have specific targets for 2024, but keeps its long-term financial targets unchanged. The CEO is talking about making additional restructuring of the business. Based on the deviation, we expect to revise up our full year '24e adj. EBIT by 5-10% following the Q3 report.
Share price view
A mixed bag in Q3 with various non-recurring items, lower sales, but higher gross margin. The stock is down ~38% YTD and down 2% over the past 5 days ahead of the report. We expect to see a positive share price reaction on the Q3 results, in similar magnitude as the expected earnings revisions. Conference call today at 10.00 CET.
Aktuellt
SENASTE
